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Dendritic cells (DCs) are required to initiate and sus-
tain T cell-dependent anti-cancer immunity. How-
ever, tumors often evade immune control by
crippling normal DC function. The endoplasmic retic-
ulum (ER) stress response factor XBP1 promotes
intrinsic tumor growth directly, but whether it also
regulates the host anti-tumor immune response is
not known. Here we show that constitutive activation
of XBP1 in tumor-associated DCs (tDCs) drives
ovarian cancer (OvCa) progression by blunting anti-
tumor immunity. XBP1 activation, fueled by lipid
peroxidation byproducts, induced a triglyceride
biosynthetic program in tDCs leading to abnormal
lipid accumulation and subsequent inhibition of tDC
capacity to support anti-tumor T cells. Accordingly,
DC-specific XBP1 deletion or selective nanopar-
ticle-mediated XBP1 silencing in tDCs restored their
immunostimulatory activity in situ and extended sur-
vival by evoking protective type 1 anti-tumor re-
sponses. Targeting the ER stress response should
concomitantly inhibit tumor growth and enhance
anti-cancer immunity, thus offering a unique
approach to cancer immunotherapy.INTRODUCTION
The endoplasmic reticulum (ER) functions primarily to process
newly synthesized secretory and transmembrane proteins.
Abnormal accumulation of unfolded proteins in this compart-
ment causes a state of ‘‘ER stress,’’ which is a hallmark feature
of secretory cells and many diseases, including diabetes, neuro-
degeneration, and cancer (Hetz et al., 2013). Adaptation to pro-
tein-folding stress is mediated by activation of an integrated
signal transduction pathway dubbed the ER stress or unfolded
protein response (UPR) that signals through three distinct stresssensors located at the ER membrane: IRE1a, ATF6, and PERK
(Hetz et al., 2013). Themost conservedUPR arm is IRE1a. During
ER stress, this kinase oligomerizes, autophosphorylates, and
uses its endoribonuclease activity to excise a 26-nucleotide
fragment from the unspliced Xbp1 mRNA (Yoshida et al., 2001)
that gives rise to functional XBP1, a potent multitasking tran-
scription factor that promotes ER chaperone expression and
regulates distinct sets of target genes in a cell type-specific
manner (Lee et al., 2003b; Yoshida et al., 2001).
Aggressive tumors evolve strategies to thrive in adverse
conditions that induce ER stress such as hypoxia, nutrient star-
vation, and oxidative stress by adjusting ER protein folding
capacity (Hetz et al., 2013). In cancer cells, XBP1 confers drug
resistance by preventing drug-induced cell-cycle arrest, mito-
chondrial permeability, and apoptosis (Gomez et al., 2007).
XBP1 drives multiple myeloma (Lee et al., 2003a) and chronic
lymphocytic leukemia (Tang et al., 2014). We recently demon-
strated that XBP1 facilitates triple-negative breast cancer
progression by promoting tumor cell survival and metastatic
capacity under hypoxic conditions (Chen et al., 2014). XBP1
expression in cancer cells directly supports tumorigenesis, but
whether it also creates a tumor-permissive immune milieu is
unknown.
In most solid cancers, nonmalignant cells such as leukocytes,
vascular cells, and fibroblasts are exposed to similarly harsh
microenvironmental conditions while stimulating tumor develop-
ment and progression (Whiteside, 2008). Leukocyte recruitment
to established cancers has pro-tumoral effects, including secre-
tion of growth factors that enhance tumor cell proliferation and
metastasis (Coussens and Werb, 2002), the induction of tumor
vascularization via paracrine mechanisms (De Palma et al.,
2007), and the orchestration of immunosuppressive networks
(Zou, 2005) that restrain the protective role of the scarce leuko-
cytes with inherent anti-tumor capacity. Ovarian tumors subvert
the normal activity of infiltrating dendritic cells (DCs) to inhibit the
function of otherwise protective anti-tumor T cells (Curiel et al.,
2003; Scarlett et al., 2012). Eliminating or ‘‘re-programming’’
tumor-associated DCs (tDCs) in vivo can abrogate ovarian can-
cer (OvCa) progression (Cubillos-Ruiz et al., 2012; Huarte et al.,
2008; Scarlett et al., 2012), but the precise molecular pathwaysCell 161, 1527–1538, June 18, 2015 ª2015 Elsevier Inc. 1527
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Figure 1. XBP1 Activation in OvCa-Associated DCs
(A) Murine CD45+CD11c+MHC-II+CD11b+CD8alow tDCs were isolated from advanced p53/K-ras-driven ovarian tumors or frommalignant ascites of mice bearing
aggressive ID8-Defb29/Vegf-A ovarian carcinoma for 4–5 weeks, and their identity as bona fide classical DCswas confirmed by quantifyingClec9A/DNGR-1 and
Zbtb46 expression (see also Figure S1). CD45+CD11c+MHC-II+CD11b+CD8a splenic DCs (sDCs) were isolated from naive or tumor-bearingmice. Xbp1 splicing
was evaluated using conventional RT-PCR. Xbp1u, unspliced form; Xbp1s, spliced form.
(B–E) DCs were isolated from naive mice or from hosts bearing ID8-Defb29/Vegf-AOvCa for 3–4 weeks. (B, D, and E) Expression of the indicated transcripts was
determined by RT-qPCR, and data were normalized to endogenous levels of Actb. (C) Western blot analysis of XBP1s expression in nuclear extracts obtained
from the indicated DCs. Lamin B was used as loading control.
(F) CD45+CD3CD20CD11c+DEC205+ tDCs were isolated from human patient ovarian tumors or metastatic OvCa ascites samples, and Xbp1 splicing was
evaluated.
(G) Expression of BiP and CHOP by all human tDC samples was analyzed.
(H) The proportion of CD45+CD3+ tumor-infiltrating lymphocytes (TILs) was correlated with tDC CHOP mRNA expression in the same human
specimen. r, Spearman’s rank correlation coefficient.that tumors exploit in DCs to co-opt their activity remain poorly
understood. Here, we uncover an unexpected role for the ER
stress response factor XBP1 as a crucial driver of DC dysfunc-
tion in OvCa-bearing hosts.
RESULTS
Robust XBP1 Activation in OvCa-Associated DCs
Myeloid cells with phenotypic features of regulatory DCs
commonly infiltrate ovarian tumors and promote malignant pro-
gression by preventing activation and expansion of tumor-reac-
tive T cells (Scarlett et al., 2012). We sought to determine
whether XBP1might drive tumor growth by inhibiting DC-depen-
dent anti-cancer immunity. Splenic and draining lymph node1528 Cell 161, 1527–1538, June 18, 2015 ª2015 Elsevier Inc.DCs from mice bearing aggressive primary and metastatic
OvCa (Conejo-Garcia et al., 2004; Scarlett et al., 2012) showed
increased splicing of Xbp1 mRNA compared with DCs from
naive hosts (Figures 1A, S1A, and S1B). However, this process
was markedly enhanced in tDCs (Figures 1A and S1C–S1F).
Quantitative analyses confirmed robust expression of total and
spliced Xbp1 mRNA in tDCs, compared with closely related
CD11c+MHC-II+CD11b+ splenic DCs (sDCs; Figure S1G) from
naive or OvCa-bearing mice (Figure 1B). Consistently, tDCs
had increased nuclear XBP1 protein compared with control
DCs from non-tumor sites (Figure 1C). Further, marked upregu-
lation of canonical XBP1 target genes ERdj4 and Sec61a1
(Acosta-Alvear et al., 2007; Lee et al., 2003b) (Figure 1D) and
general ER stress response markers Hspa5 (BiP) and Ddit3
AE
I J K L
F G H
B C D
Figure 2. OvCa Progression in Hosts Lacking XBP1 in DCs
(A) p53/K-ras-driven ovarian tumors were generated in hosts reconstituted with BM from either XBP1f/f (top) or XBP1f/f CD11c-Cre (bottom) donor mice. p53
deletion and oncogenic KRAS expression were induced via intrabursal injection of Cre-expressing adenovirus (ADV-Cre), as described in the Supplemental
Experimental Procedures, and primary tumors were resected 7 weeks later.
(B) Growth kinetics of p53/K-ras-driven tumors shown in (A).
(C and D) Mice bearing primordial p53/K-ras-driven tumors for 28 days were injected i.p. with WT or XBP1-deficient (KO) BMDCs, and tumor growth was
monitored over time until day 71.
(E–H) Mice of the indicated genotypes were implanted with ID8-Defb29/Vegf-AOvCa cells via i.p. injection. (E and F) Peritoneal metastases evaluated 3–4 weeks
after tumor implantation (n = 3 per group). (G) Malignant ascites generation in tumor-bearing mice expressed as percent weight gain due to progressive
accumulation of peritoneal fluid. (H) Reduced splenomegaly in tumor-bearing mice deficient for XBP1 in CD11c+ DCs.
(I and J) Survival inmice bearing aggressive ID8-Defb29/Vegf-A (I) or parental ID8 (J) tumors. Data are representative of at least two independent experimentswith
similar results using four to six mice per group.
(K and L) ID8-Defb29/Vegf-A cancer cells were implanted in the flank alone or in combination withWT or XBP1-deficient (KO) BMDCs. Tumors were resected and
measured 40 days later. *p < 0.05, **p < 0.001. Error bars represent SEM.(CHOP) occurred only in tDCs (Figure 1E). Constitutive Xbp1
splicing was also observed in tDCs isolated frommultiple human
OvCa specimens (Figures 1F, S1H, and S1I), and expression
levels of ER stress markers BiP and CHOP positively correlated
in these human samples (Figure 1G). Interestingly, increased
CHOP expression in tDCs was associated with reduced T cell
infiltration in human OvCa specimens (Figure 1H), suggesting
that ER-stressed DCs may regulate T cell anti-tumor responses.
Hence, DCs in the OvCamicroenvironment exhibit marked upre-
gulation of ER stress response markers and robust XBP1
activation.
DC-Intrinsic XBP1 Is Required for Optimal OvCa
Progression
We next developed aggressive orthotopic ovarian tumors in
conditional knockout female mice lacking functional XBP1 in
DCs. Genetically modified mice harboring exon 2 of Xbp1
flanked by two loxP sites (Lee et al., 2008) were crossed with
mice expressing Cre recombinase under control of the integrinalpha X (Itgax) promoter (termed CD11c-Cre) (Figures S2A–
S2C) that deletes selectively in conventional DCs (Caton et al.,
2007). Consistent with recent reports (Osorio et al., 2014), con-
ditional XBP1 deletion through CD11c-controlled Cre solely
affected the proportion and number of splenic CD8a+ DCs (Fig-
ures S2D–S2L). The frequency of tDCs, which are mainly CD8a-
low (Figure S1E), was not altered in mice bearing orthotopic
OvCa (Figures S2G–S2J), indicating that XBP1 is dispensable
for DC survival in the OvCa microenvironment. However, the
development of p53/K-ras-driven primary OvCa (Scarlett et al.,
2012) was significantly compromised in irradiated hosts recon-
stituted with XBP1f/f CD11c-Cre donor bone marrow (BM)
compared with control hosts transplanted with XBP1-sufficient
(XBP1f/f) littermate BM (Figures 2A and 2B). Tumor growth
was also inhibited in mice bearing primordial p53/K-ras-driven
OvCa upon intraperitoneal (i.p.) injection of XBP1-deficient,
but not WT, BM-derived DCs (BMDCs) (Figures 2C and 2D).
Hence, XBP1 expression in CD11c+ DCs is crucial for the rapid
initiation and progression of primary OvCa, and DCs devoid ofCell 161, 1527–1538, June 18, 2015 ª2015 Elsevier Inc. 1529
XBP1 in the tumor microenvironment show enhanced capacity
to restrain tumor growth.
Since the vast majority of OvCas are diagnosed at advanced
stages, with disease spread throughout the peritoneal cavity,
we examined how DC-localized XBP1 impacts progression of
orthotopic tumors that closely recapitulate human metastatic
OvCa (Conejo-Garcia et al., 2004). Notably, OvCa-bearing
female mice lacking functional XBP1 in DCs demonstrated
reduced peritoneal tumor burden (Figures 2E and 2F), impaired
ascites accumulation (Figure 2G), and diminished tumor-
induced splenomegaly (Figure 2H) compared with control
(XBP1f/f) littermates. Consequently, these hosts displayed an
30% increase in median survival compared with control litter-
mates (Figure 2I). Similar survival results were observed in
XBP1f/f CD11c-Cre mice developing parental orthotopic ovarian
tumors (Roby et al., 2000) that do not ectopically expressDefb29
and Vegf-A (Figure 2J). Further confirming the detrimental role of
DC-intrinsic XBP1 in OvCa, implantation of malignant cells
admixed with WT BMDCs markedly promoted the growth of
solid ID8-based ovarian tumors, whereas XBP1-deficient
BMDCs significantly impaired this process (Figures 2K and 2L).
Together, these results demonstrate that XBP1 expression in
DCs is necessary for the accelerated and aggressive progres-
sion of primary and metastatic OvCas in three preclinical models
of disease.
Byproducts of Lipid Peroxidation Trigger ER Stress
in DCs
Constitutive XBP1 activation in tDCs suggested that cancer-
derived factors in the tumor microenvironment might trigger ER
stress in innate immune cells to blunt anti-tumor immunity.
Interestingly, neither tumorigenic/immunosuppressive cytokines
commonly enriched at tumor sites nor hypoxia-mimicking condi-
tions caused robust XBP1 activation in naive DCs (Figures S3A–
S3C). Abnormal intracellular accumulation of peroxidized lipids
is a common feature of dysfunctional DCs infiltrating several hu-
man and murine cancers (Herber et al., 2010; Ramakrishnan
et al., 2014). Intracellular lipid oxidation by reactive oxygen spe-
cies (ROS) generates multiple reactive byproducts such as
the unsaturated aldehyde 4-hydroxy-trans-2-nonenal (4-HNE),
shown to induce protein-folding stress by forming stable ad-
ducts with ER-resident chaperones (Vladykovskaya et al.,
2012). Hence, we hypothesized that this diffusible and highly
reactive aldehyde (Uchida et al., 1999) might trigger ER stress
in tDCs. OvCa-associated DCs demonstrated significantly
higher amounts of intracellular lipids and augmented ROS levels
in comparison with control sDCs isolated from the same host or
from naive mice (Figures 3A and 3B). Consistent with active lipid
peroxidation, we found intracellular 4-HNE-protein adducts in
tDCs isolated from human and mouse tumors (Figure 3C), and
increased levels of this aldehydewere present in tDCs compared
with sDC of OvCa-bearing mice (Figure 3D). Extracellular 4-HNE
was not enriched in cell-free ascites or serum from OvCa-
bearing hosts (Figures S3D and S3E), suggesting that this reac-
tive aldehyde is mostly generated intracellularly due to the high
lipid and ROS content in tDCs (Figures 3A and 3B). Indeed, naive
sDCs exposed to cell-free OvCa ascites rapidly generated intra-
cellular 4-HNE-protein adducts in a dose-dependent manner1530 Cell 161, 1527–1538, June 18, 2015 ª2015 Elsevier Inc.(Figure 3E). Proteomic analyses confirmed the presence of
several intracellular proteins modified by the endogenous
4-HNE generated in naive DCs exposed to OvCa ascites super-
natants, but not in control untreated DCs (Table S1). Of note,
ascites-induced 4-HNE modified key ER-resident chaperones
such as Grp78/BiP and ERdj3/Dnajb11 (Figures 3F and 3G). In-
duction of 4-HNE-protein adducts by ascites was inhibited
when DCs were treated with the ROS-scavenging agent vitamin
E or with hydralazine (Figure 3H), a hydrazine derivative (Fig-
ure S3F) previously shown to sequester reactive lipid peroxida-
tion byproducts (Galvani et al., 2008). Treatment of freshly
isolated tDCs with either vitamin E or hydralazine inhibited
Xbp1 splicing and prevented induction of general ER stress
response markers triggered by ascites exposure (Figures 3I
and 3J). Further, induction of Xbp1 splicing and upregulation of
ER stress response markers was observed in naive sDC
exposed to 4-HNE concentrations generating intracellular
adduct levels similar to those generated upon incubation with
cell-free ascites (Figures S3G–S3I). Together, these data indi-
cate that lipid peroxidation byproducts, abundant in OvCa
tDCs, promote ER stress and constitutive XBP1 activation.
Constitutive XBP1 Activation Disrupts DC Homeostasis
Transcriptional profiling of WT versus XBP1-deficient DCs in
OvCa ascites identified 416 significantly downregulated and
237 significantly upregulated genes (Table S2). These altered
gene subsets were analyzed to identify transcriptional regulators
that may explain the observed mRNA changes. Several pre-
dicted regulators were identified (Figure S4A), and XBP1, as ex-
pected, was a key node in the most highly represented gene
network emerging from this analysis (Figure S4B). Interestingly,
gene networks regulated by the immunosuppressive transform-
ing growth factor-b (TGF-b), but not TGF-b itself, were sup-
pressed in XBP1-deficient tDCs (Figure S4A). Multiple known
XBP1 and UPR target genes (Acosta-Alvear et al., 2007; Lee
et al., 2003b) were markedly repressed in XBP1-deficient tDCs
(Figure 4A), confirming sustained ER stress in DCs infiltrating
OvCa. Expression of known regulated IRE1a-dependent decay
(RIDD) target mRNAs (Hetz et al., 2013; Hollien et al., 2009;
Osorio et al., 2014) was unchanged betweenWT and XBP1-defi-
cient tDCs (Figure S4C), ruling out IRE1a artificial overactivation
due to absence of functional XBP1. We found four significantly
enriched functional categories, including carbohydrate and lipid
metabolic processes, protein localization and transport, and
regulation of cell communication (Figure S4D). Of particular inter-
est, tDCs devoid of XBP1 displayed marked downregulation of
multiple genes involved in lipid metabolic pathways and espe-
cially, in triglyceride biosynthesis (Figure 4B). Given the strong
association between excessive lipid accumulation and DC
dysfunction in cancer (Herber et al., 2010; Ramakrishnan et al.,
2014), we investigated XBP1 as a potential mediator of this pro-
cess. Consistent with sustained ER stress at tumor locations,
OvCa-associated DCs exhibitedmarked upregulation ofmultiple
XBP1-controlled triglyceride biosynthetic genes (Figure 4B),
including Agpat6, Fasn, Scd2, and Lpar1 (Figure S5A), and these
genes were rapidly induced in naive sDCs exposed to 4-HNE
(Figure S5B). OvCa-infiltrating DCs lacking XBP1 showed
reduced intracellular lipid content compared with WT tDCs
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Figure 3. Lipid Peroxidation Byproducts Trigger ER Stress in DCs
(A) Intracellular lipid content in DC populations from naive or tumor-bearing mice (OvCa). (Left) Representative FACS analysis of lipid staining for DCs from the
indicated sources. (Right) Lipid quantification expressed as mean fluorescence intensity (MFI) of Bodipy 493/503 staining.
(B) Intracellular ROS levels in sDCs or in tDCs untreated or treated with vitamin E (VitE). Data are expressed as geometric MFI (gMFI) of DCFDA staining.
(C) Intracellular 4-HNE-protein adducts in tDCs from human or mouse metastatic OvCa ascites samples.
(D) Levels of 4-HNE-protein adducts in tDCs compared with control sDCs from tumor-bearing mice.
(E) Dose-dependent increase in intracellular 4-HNE-protein adducts in sDCs exposed to ascites supernatants.
(F) MS/MS spectrum on the doubly charged precursor atm/z 909.00, identifying a tryptic peptide with 4-HNE forming a Michael adduct on the Lys214 residue of
the peptide from the 78 kDa glucose-regulated protein precursor (GRP78/BiP).
(G) MS/MS spectrum on the triply charged precursor atm/z 643.32, identifying a tryptic peptide with 4-HNE forming aMichael adduct on the Lys82 residue of the
peptide from the dnaJ homolog subfamily B member 11 precursor (ERdj3/Dnajb11).
(H) Intracellular levels of 4-HNE protein adducts in sDCs exposed to cell-free ascites in the presence or absence of VitE or Hydralazine (Hlz) for 18 hr.
(I and J) tDCwere pretreated with VitE or Hlz and then incubated in normal media (gray bars) or in media supplemented with 25% cell-free ascites (green bars) for
18 hr. Expression of the indicated transcripts was assessed via RT-qPCR. Data are normalized toActb expression in each sample. #p < 0.05 comparedwith tDC in
ascites-free media. *p < 0.05 compared with ascites-exposed untreated tDC. Error bars represent SEM.(Figure 4C) and displayed a marked decrease in the number of
cytosolic lipid droplets (Figures 4D and 4E), as well as reduced
intracellular levels of total triglycerides (Figure 4F). Other lipid
classes were unaffected (Figure S5C), and these observations
were confirmed by analyzing cell-free ascites supernatants (Fig-ure S5D). Decreased intracellular lipid content in XBP1-deficient
tDCs was not due to defective expression of genes encoding
scavenger receptors (Cd36, Cd68,Msr1) implicated in extracel-
lular lipid uptake (Figure S5E). Notably, exposure to cell-free
OvCa ascites augmented the intracellular lipid content of mouseCell 161, 1527–1538, June 18, 2015 ª2015 Elsevier Inc. 1531
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Figure 4. XBP1 Disrupts Lipid Homeostasis in OvCa-Associated DCs
(A and B) Downregulation of genes involved in the UPR/ER stress response (A) and lipid metabolism (B) in tDCs devoid of XBP1. WT is XBP1f/f tDC. XBP1def is
XBP1f/f CD11c-Cre tDC (n = 3 per group). Black dots indicate genes involved in triglyceride biosynthesis.
(C) Decreased intracellular lipid content in XBP1f/f CD11c-Cre tDCs (n = 3 mice per group) frommice bearing ID8-Defb29/Vegf-A tumors for 3 weeks revealed by
Bodipy493/503 staining.
(D) Electron micrographs (12,0003) showing large intracellular lipid bodies (red arrows) in XBP1-sufficient, but not XBP1-deficient, tDC. Black scale bars
represent 2 mm.
(E and F) Quantification of lipid bodies (E) and intracellular triacylglycerides (TAGs) (F) in tDCs sorted from mice bearing ID8-Defb29/Vegf-A ovarian tumors for
3–4 weeks.
(G) tDCs were incubated in vitro with or without 25% cell-free OvCa ascites in the presence of 4m8c, TOFA, Tiron, or VitE. Intracellular lipid content was assessed
24 hr later via Bodipy493/503 staining. Data are representative of three independent experiments with similar results. #p < 0.05 compared with control tDC
incubated in the absence of cell-free ascites supernatants. *p < 0.05 compared with ascites-exposed tDC but left untreated. Error bars represent SEM.tDCs and was prevented by concurrent treatment with TOFA, an
inhibitor of fatty acid synthesis (Figures 4G and S5F). Pharmaco-
logical inhibition of IRE1a/XBP1 activation using the IRE1a inhib-
itor 4m8c also reduced ascites-driven lipid biogenesis in tDCs
(Figures 4G and S5F). Consistent with ROS as key generators
of XBP1-activating 4-HNE (Figure 3), treatment of tDCs with
the global ROS scavenger vitamin E, but not with the superox-
ide-specific scavenger Tiron reduced intracellular lipid content
(Figures 4G and S5F). Further, sequestering intracellular 4-HNE
using hydralazine also prevented ascites-induced lipid biogen-
esis in tDCs (Figure S5G). Taken together, the transcriptomic
and functional data indicate that sustained activation of XBP1
disrupts intracellular lipid homeostasis in OvCa-associated DCs.
XBP1-Deficient tDCs Support T Cell Activation
Aberrant lipid accumulation by tDCs obstructs their normal
antigen-presenting capacity, ultimately blunting anti-tumor im-1532 Cell 161, 1527–1538, June 18, 2015 ª2015 Elsevier Inc.mune responses (Herber et al., 2010; Ramakrishnan et al.,
2014). T cells are the sole immune population that exerts
significant pressure against OvCa, and the magnitude of
intra-tumoral T cell infiltration strongly correlates with better
outcome in OvCa patients (Curiel et al., 2003; Zhang et al.,
2003). Hence, XBP1-deficient tDCs with reduced intracellular
lipids might support rather than repress T cell activation
and function at tumor sites. Incubation of BMDCs in tumor-
conditioned media (TCM) induced Xbp1 splicing (Figure S6A)
and subsequent triglyceride accumulation (Figure S6B), leading
to decreased surface expression of MHC-I complexes loaded
with intracellularly processed peptide (ovalbumin [OVA]-derived
SIINFEKL) (Figure S6C). Accordingly, BMDCs pulsed with full-
length OVA protein in the presence of TCM, compared with
normal culture media, had reduced capacity to induce OT-1
T cell proliferation (Figure 5A). This impairment was also
observed upon incubation with the ER stressor tunicamycin
Figure 5. XBP1 Promotes DC Malfunction in the OvCa Microenvironment
(A) WT BMDCs were left untreated or treated with tunicamycin (Tm), oleate, or TCM for 8 hr and then pulsed overnight with 100-mg/ml full-length OVA protein.
CFSE-labeled OT-1 T cells were co-cultured with treated BMDCs, and proliferation was assessed by FACS 3 days later.
(B) WT or XBP1-deficient (KO) BMDCs were incubated in 25% TCM for 8 hr, and the proliferation assay was repeated as described in (A).
(C) CFSE-dilution analysis of OT-1 T cells co-cultured with OVA protein-pulsed tDCs isolated from the peritoneal cavity of XBP1f/f or XBP1f/f CD11c-Cre mice
bearing ID8-Defb29/Vegf-A ovarian tumors for 4 weeks. tDCs were treated or untreated with vitamin E (VitE) during the OVA pulse.
(D and E) Enhanced endogenous T cell activation at tumor sites in mice devoid of XBP1 in tDCs. Peritoneal wash samples fromWT (XBP1f/f, black bars) or XBP1-
deficient (XBP1f/f CD11c-Cre, gray bars) mice were collected 2–3 weeks after peritoneal implantation of ID8-Defb29/Vegf-A OvCa cells. Surface expression of
CD44 and intracellular levels of tumoricidal IFN-g were analyzed on CD3+CD4+ (D) or CD3+CD8+ (E) tumor-infiltrating T cells (TILs).
(F) Proportion of T regulatory cells at tumor locations in mice of the indicated genotypes bearing metastatic ID8-Defb29/Vegf-A ovarian tumors for 3 weeks. In all
cases, data are representative of two independent experiments using three to four mice per group.
(G and H) Growth of solid ID8-Defb29/Vegf-A ovarian tumors in hosts adoptively transferred with splenic and draining lymph node T cells isolated from XBP1 f/f or
XBP1f/f CD11c-Cre mice bearing metastatic tumors for 30 days. Error bars represent SEM.
Cell 161, 1527–1538, June 18, 2015 ª2015 Elsevier Inc. 1533
or by enforcing lipid accumulation using oleate during antigen
loading (Figure 5A). In contrast, XBP1-deficient BMDCs unable
to accumulate triglycerides upon TCM exposure (Figure S6B)
did not show significant reduction in surface levels of pep-
tide-loaded MHC-I complexes when pulsed under this condi-
tion (Figure S6C). This effect was not due to enhanced OVA
cleavage (Figure S6D) or increased expression of MHC-I by
XBP1-deficient BMDCs (Figure S6E). Consequently, BMDCs
lacking XBP1 demonstrated enhanced capacity to induce the
proliferation of OT-1 T cells when pulsed with OVA under
TCM, compared with their WT counterparts pulsed likewise
(Figure 5B).
XBP1-deficient tDCs pulsed with full-length OVA or apoptotic
OVA-expressing tumor cells in the presence of ascites also had
enhanced capacity to induce OT-1 T cell expansion, compared
with WT tDCs (Figures 5C and S6F–S6H), and these differences
were not due to reduced PD-L1 expression by XBP1-deficient
tDC (Figure S6I). Consistent with impaired lipid accumulation
upon global ROS scavenging and IRE1a/1 inhibition (Figure 4G),
pre-treatment of WT tDC with vitamin E phenocopied the
improved antigen-presenting capacity of XBP1-deficient tDCs
(Figure 5C). Further supporting the enhanced function of
XBP1-deficient DCs at tumor locations, p53/K-ras ovarian tu-
mors developed in irradiated hosts reconstituted with XBP1f/f
CD11c-Cre BM (Figure 2A) demonstrated an 7-fold increase
in the levels of intratumoral T cell infiltration compared with tu-
mors developed in mice reconstituted with WT BM (Figure S6J).
Most of these CD4+ T cells were antigen experienced (CD44+),
and a significant proportion expressed the Th1-polarizing tran-
scription factor T-bet (Figure S6K). The majority of CD8+ T cells
present in p53/K-ras tumors generated in XBP1-deficient hosts
also expressed CD44 and a proportion of those produced
Granzyme B in situ (Figure S6L). Reduced PD-1 levels were
observed on these cells compared with the few CD8+ T cells
poorly infiltrating p53/K-ras tumors developed in mice reconsti-
tuted with WT BM (Figure S6M). While PD-1 levels remained un-
altered on peritoneal T cells in XBP1f/f or XBP1f/f CD11c-Cre
mice harboring metastatic ID8-based OvCa (Figure S6N), the
latter demonstrated a marked increase in the proportion of infil-
trating CD44+IFNg-secreting CD8+ and CD4+ T cells at tumor
sites (Figures 5D and 5E). In addition, the proportion of
Foxp3+ T regulatory cells infiltrating tumor locations was signif-
icantly lower in XBP1-deficient hosts (Figure 5F). To functionally
demonstrate that the enhanced activity of XBP1-deficient DCs
in OvCa results in improved T cell-mediated anti-tumor re-
sponses, orthotopic ovarian tumors were developed in WT or
XBP1-deficient hosts, and T cells were obtained from spleens
and draining lymph nodes 30 days after tumor implantation.
Isolated T cells were independently transferred into naive
mice, and hosts were then challenged with ovarian tumors in
the flank. Notably, T cells obtained from tumor-bearing mice
lacking XBP1 in DCs demonstrated improved capacity to
restrain tumor growth in adoptively transferred hosts,
compared with untreated mice or control mice receiving
T cells isolated from WT OvCa-bearing mice (Figures 5G and
5H). Together, these data indicate that constitutive XBP1 acti-
vation promotes anti-tumor immune tolerance by OvCa-associ-
ated DCs.1534 Cell 161, 1527–1538, June 18, 2015 ª2015 Elsevier Inc.Therapeutic XBP1 Silencing in tDCs Extends Host
Survival by Inducing Anti-tumor Immunity
Silencing XBP1 expression in OvCa-associated DCs could
potentially restore their immunogenic attributes in situ to pro-
mote the function of infiltrating anti-tumor T cells. To selectively
target XBP1 in tDCs, we utilized our previously optimized system
of polyethylenimine (PEI)-based nanoparticles encapsulating
siRNA (Cubillos-Ruiz et al., 2009, 2012). These nanocomplexes
are preferentially and avidly engulfed by abundant phagocytic
tDCs upon i.p. injection, enabling selective in vivo gene silencing.
Also, PEI-based nanoparticles inherently activate OvCa-associ-
ated DCs by triggering TLR signaling that induces potent immu-
noadjuvant activity against tumors (Cubillos-Ruiz et al., 2009).
Confirming previous findings, nanoparticles were selectively
taken up by tDCs present in malignant ascites of mice bearing
metastatic OvCa (Figure S7A). PEI-based nanocomplexes deliv-
ering Xbp1-specific siRNA induced 65% gene silencing in
target tDC compared with control luciferase-targeting siRNA
nanoparticles (Figure S7B). The functional effects of gene
silencing were confirmed by the decreased expression of the
canonical XBP1 targets EDEM and Sec61a1, as well as lipid
biosynthesis-related Agpat6 and Scd2 in tDCs (Figure S6C).
Further, tDCs isolated from mice treated with either XBP1- or
IRE1a-targeting nanoparticles demonstrated reduced triglycer-
ide levels compared with control tDCs (Figure S7D), and the
in vivo proliferation of adoptively transferred CFSE-labeled
OT-1 T cells in the OvCa microenvironment was significantly
enhanced in mice pulsed i.p. with full-length OVA protein when
XBP1 expression was specifically silenced in tDCs (Figures
6A–6C). Therapeutic administration of Xbp1-silencing nanocom-
plexes reduced the number of metastatic cancer cells in the
peritoneal cavity (Figure 6D) and diminished malignant ascites
accumulation (Figure 6E). These effects occurred concomitantly
with enhanced infiltration of endogenous antigen-experienced/
activated T cells at tumor locations compared with control nano-
particles (Figure 6F). Indeed, silencing XBP1 expression in tDCs
markedly enhanced the capacity of infiltrating T cells to respond
to tumor antigens, as evidenced by ex vivo interferon-g (IFN-g)
and Granzyme B secretion using BMDCs pulsed with tumor
antigens (Figure 6G). Splenic T cells isolated from mice
treated with XBP1-silencing nanocomplexes also demonstrated
improved responses upon exposure to tumor antigens in similar
re-call assays (Figure 6H), indicating development of enhanced
anti-tumormemory responses. These data reinforce the concept
that abrogating XBP1 function in tDCs enables the activation and
expansion of endogenous anti-tumor T cells in vivo.
To determine whether abrogation of the IRE1a/XBP1 pathway
selectively in tDCs had significant therapeutic effects, mice
bearing aggressive orthotopic ovarian tumors were i.p. treated
with saline, non-targeting or gene-specific siRNA-PEI nanocom-
plexes. Treatments started 12 days after tumor implantation, and
injections were administered every 4 days for a period of
3 weeks. Interestingly, WT mice treated with either XBP1- or
IRE1a-silencing nanoparticles demonstrated a marked increase
in survival compared with control groups, reinforcing depen-
dence of this phenotype on spliced Xbp1 rather than RIDD (Fig-
ure 7A). However, Rag2-deficient hosts bearing ovarian tumors
were unable to respond to this treatment, demonstrating that
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Figure 6. Therapeutic Silencing of XBP1 Improves tDC Function and Evokes Anti-tumor Immunity
(A) Representative CFSE dilution of OT-1 T cells proliferating in vivo at tumor sites in OVA protein-pulsed untreated mice or after administration of
immunostimulatory nanocomplexes carrying luciferase-matching (siLuc-PEI) or XBP1-specific (siXBP1-PEI) siRNA.
(B) Proportion of OT-1 T cells in ascites of treated mice (n = 3 per group) 3 days after transfer.
(C) Division and proliferation index of transferred OT-1 T cells shown in (B).
(D–H) Enhanced anti-tumor immune responses inmice treatedwith DC-targeting, XBP1-silencing nanocomplexes. ID8-Defb29/Vegf-A tumor-bearingmice (n = 3
per group) were treated at days 8, 13, 18, and 23 post-tumor injection, and peritoneal lavage samples were analyzed at day 27. (D) Proportion of metastatic tumor
cells (CD45SSChi) found in the peritoneal cavity of treated mice. (E) Representative pictures of peritoneal lavages obtained from treated mice. (F) Proportion of
antigen-experienced (CD44+), activated (CD69+) CD4+ (left), and CD8+ (right) T cells infiltrating tumor locations determined by FACS analyses (gated on CD3+
cells). (G and H) Representative ELISA-based analysis showing increased IFN-g and Granzyme B secretion by peritoneal (G) and splenic (H) T cells isolated from
mice treated with XBP1-silencing nanoparticles. Error bars represent SEM.an intact adaptive immune system is necessary for the observed
therapeutic benefit (Figure 7B). Together, these data indicate
that targeting the IRE1a/XBP1 branch of the ER stress response
in tDCs induces protective immune responses against OvCa.
DISCUSSION
Here we uncover an unexpected role for the ER stress response
factor XBP1 as a central driver of DC malfunction in the tumor
microenvironment. Our findings suggest a strategy whereby a
lethal cancer exploits the most conserved arm of the ER stress
response in tumor-resident DCs to disrupt their homeostasis,alter their local antigen-presenting capacity, and ultimately
evade T cell-mediated immune control. While the ER stress
response, and especially XBP1 activation, was previously shown
to promote tumorigenesis, we now propose that this integrated
cellular pathway further supports malignant progression by in-
hibiting the development of protective anti-tumor immunity via
manipulation of normal DC function.
Gabrilovich and colleagues have elegantly demonstrated that
cancer-associated DCs accumulate substantial amounts of
oxidized lipids that diminish their antigen-presenting ability
(Herber et al., 2010; Ramakrishnan et al., 2014). Our transcrip-
tional and functional analyses suggest that XBP1 plays a crucialCell 161, 1527–1538, June 18, 2015 ª2015 Elsevier Inc. 1535
A B Figure 7. Therapeutic Effects of Targeting
IRE1a/XBP1 Signaling in OvCa DCs
(A and B) Survival analysis in WT (A) or Rag2-
deficient (B) OvCa-bearing mice (n = 6 per group)
treated with nanocomplexes at days 12, 16, 20, 24,
28, and 32 after implantation of ID8-Defb29/Vegf-A
cancer cells. Data are representative of two inde-
pendent experiments with similar results. ***p <
0.001, log-rank test.role in promoting aberrant lipid accumulation by dysfunctional
tDCs and that lipid peroxidation byproducts, like 4-HNE, sustain
ER stress and fuel constitutive XBP1 activation in tDCs. Interest-
ingly, 4-HNEwas shown to induce the UPR in endothelial cells by
forming covalent adducts with ER resident chaperones, thereby
promoting vascular inflammation and atherosclerosis (Vladykov-
skaya et al., 2012). Consistent with previous reports linking XBP1
and lipid biosynthesis (Lee et al., 2008; Sriburi et al., 2004), we
found that enhanced intracellular lipid accumulation by tDCs
required ROS generation and IRE1a/XBP1 activation. Interest-
ingly, exposure to 4-HNE is sufficient for promoting fat accumu-
lation in worms and mice (Singh et al., 2008, 2009). Other lipid
peroxidation byproducts like acrolein, malondialdehyde, and
4-hydroxyhexenal form stable adducts with cellular proteins
(Negre-Salvayre et al., 2008), suggesting that they might also
induce immunosuppression in the tumor microenvironment by
triggering ER stress in infiltrating innate immune cells. Further,
chemotherapeutic agents are known to induce oxidative stress
and subsequent 4-HNE generation (Velez et al., 2011), suggest-
ing that chemotherapy might promote ‘‘tumorigenic ER stress’’
in cells of the tumor microenvironment. This is particularly rele-
vant to OvCa, as patients diagnosed with this disease show
persistent, refractory, or recurrent cancer following treatment
with surgery and first-line chemotherapy. Notably, the status of
lipid peroxidation at the time of tumor removal has been sug-
gested as a putative marker of disease recurrence in breast can-
cer patients (Herrera et al., 2014).
Our findings suggest a model in which reactive metabolic by-
products induced by the tumor microenvironment, like 4-HNE,
can initiate and sustain pro-tumorigenic ER stress in infiltrating
tDCs. Constitutive activation of the IRE1a/XBP1 arm through
this process disrupts global tDC homeostasis and consequently
inhibits tDC capacity to locally support T cell-mediated anti-
tumor responses. Since splenic and draining lymph node DCs
of OvCa mice also showed increased levels of Xbp1s compared
with naive hosts, it is reasonable to consider that XBP1 might
also regulate anti-tumor immunity by operating in DCs residing
in lymphoid organs that may have migrated from the primary
tumor site.
Activating T cell immunity to eliminate tumor cells is the most
promising anti-cancer strategy since the development of
chemotherapy, as demonstrated by the shrinkage of melanoma
in response to checkpoint blockers. Further, adoptively trans-
ferred anti-tumor T cells (expanded from tumor specimens or
genetically manipulated) can elicit robust and long-lasting anti-
tumor responses (Bollard et al., 2007; Morgan et al., 2006). How-1536 Cell 161, 1527–1538, June 18, 2015 ª2015 Elsevier Inc.ever, in most cases, the optimal cytotoxic activity of such
tumor-reactive T cells is drastically reduced precisely because
cancer-associated DCs are unable to support T cell function
(Curiel et al., 2003; Scarlett et al., 2012). Our results reveal that
DC-specific deletion of XBP1 can extend host survival by con-
verting immunosuppressive tDCs into activators of type 1 immu-
nity in OvCa-infiltrating T cells. Indeed, therapeutic silencing of
XBP1 in tDCs using siRNA-encapsulating nanocarriers reversed
their immunosuppressive phenotype and prolonged host sur-
vival by inducing protective anti-tumor immune responses.
Novel and more effective therapeutic strategies are urgently
needed to improve the dismal prognosis of patients with meta-
static OvCa and other lethal cancers. Our study demonstrates
the feasibility and immunotherapeutic potential of targeting
ER stress-driven XBP1 selectively in tDCs using a nanotech-
nology-based system that may slow or prevent the usually inev-
itable recurrence observed in OvCa patients who have been
‘‘optimally’’ debulked. Targeting IRE1a/XBP1 signaling in can-
cer-bearing hosts with small molecule IRE1a inhibitors could
induce two parallel, mutually reinforcing anti-tumor mecha-
nisms: the direct inhibition of cancer cell survival and the simul-
taneous induction of protective anti-tumor immunity.
EXPERIMENTAL PROCEDURES
Tissues, Mice, and Cell Lines
Stages III–IV human OvCa specimens and malignant ascites samples were
procured through Surgical Pathology at Weill Cornell under an approved
protocol where research samples remained unidentified. Tumor single-cell
suspensions were generated as described (Conejo-Garcia et al., 2004).
Malignant peritoneal ascites samples from patients with metastatic OvCa
were centrifuged for 10 min at 1,300 rpm, and red blood cells were lysed prior
to fluorescence-activated cell sorting (FACS) analysis. Mice were housed at
the animal facilities of Harvard School of Public Health, Weill Cornell, or
The Wistar Institute. Our Institutional Animal Care and Use Committees
approved all animal experiments described in this study. Transgenic mouse
strains and tumor models used are described in the Supplemental Experi-
mental Procedures.
Isolation of Human and Mouse DCs
Human patient OvCa-associated DCs (CD45+CD3CD20CD11c+DEC205+)
were sorted from tumor single-cell suspensions or malignant ascites using
flow cytometry, following the gating strategy in Figure S1. During sorting,
viable cells were identified using the LIVE/DEAD Fixable Yellow Dead Cell
Stain Kit (Life Technologies). Mouse OvCa-associated DCs (CD45+CD11c+
CD11b+MHC-II+CD8alow) were sorted from single-cell suspensions of p53/
K-ras-driven ovarian tumors or from peritoneal wash (10 ml 13 PBS) or malig-
nant ascites samples from mice bearing aggressive ID8-Defb29/Vegf-A i.p.
OvCa, per gating strategy (Figure S1). All fluorescently labeled antibodies
were from BioLegend. Control sDCs (CD45+CD11c+CD11b+MHC-II+CD8a)
were FACS sorted from spleens of naive or OvCa-bearing mice using
Collagenase D and DNase I treatment followed by incubation with the indi-
cated antibodies. In all cases, BMDCs were generated from naive XBP1f/f
(WT) or XBP1f/f CD11c-Cre (XBP1 deficient) BM via incubation in media sup-
plemented with 20 ng/ml recombinant granulocyte macrophage colony-stim-
ulating factor (GMCSF) (Gemini) (Scarlett et al., 2012). Cells were harvested at
day 7 of expansion and used directly for subsequent in vitro or in vivo func-
tional assays.
Reagents and In Vitro Cellular Treatments
Murine recombinant cytokines were purchased from Peprotech. Cobalt chlo-
ride (10–100 mM), tunicamycin (1 mg/ml), Tiron (100–500 mM), vitamin E
(a-tocopherol, 50–100 mM) and hydralazine (100 mg/ml) were from Sigma.
20,70-dichlorofluorescin diacetate (DCFDA) staining was utilized for intracel-
lular ROS detection (Abcam). Purified 4-HNE (Cayman Chemical) and
4-HNE-protein adducts in ascites samples and DCs were detected and quan-
tified through competitive ELISA (Cell Biolabs). 5-tetradecyl-oxy-2-furoic acid
(TOFA) (Cayman Chemical) was used at a final concentration of 5 mg/ml to
inhibit fatty acid synthesis in DCs. The IRE1a-specific inhibitor 4m8c (Millipore)
was used at 10 mM and DQ-OVA (Invitrogen) at 50 mg/ml. Cell-free (0.22 mm-
filtered) TCM was harvested from ID8-Defb29/Vegf-A OvCa cells grown to
confluency in complete Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS).
RNA-seq and DC Transcriptional Profile
tDCs were sorted from peritoneal wash samples of XBP1f/f or XBP1f/f CD11c-
Cre female mice (n = 3 per group) bearing aggressive ID8-Defb29/Vegf-A
ovarian tumors for 3 weeks. Total RNA was isolated using the miRVANA
miRNA isolation Kit (Life Technologies), further concentrated via RNeasy
MinElute columns (QIAGEN) and RNA quality and integrity confirmed in an Agi-
lent Bioanalyzer 2100. In all cases, RINs were 9.50 or higher. mRNA libraries
were generated and sequenced at the Weill Cornell Epigenomics Facility. All
primers used in this study are described in Table S3; Supplemental Information
for details.
Flow Cytometry and Lipid Staining
Intracellular lipid content was evaluated via flow cytometry using 4,4-Difluoro-
1,3,5,7,8-Pentamethyl-4-Bora-3a,4a-Diaza-s-Indacene (BODIPY 493/503;
Life Technologies) (Herber et al., 2010). Briefly, 5x106 splenic or malignant
peritoneal wash cells were stained for surface markers using antibodies that
do not overlap with BODIPY 493/503, namely CD11c-APC, CD45-APC-Cy7,
and CD11b-Pacific Blue, followed by staining with 500 ml of BODIPY 493/
503 at 0.5 mg/ml in PBS for 15 min at room temperature in the dark. BODIPY
493/503 staining was detected in the PE channel. For intracellular cytokine
staining, 5 3 106 cells from malignant peritoneal wash samples were stimu-
lated for 6 hr in 10% FBS complete RPMI containing phorbol myristate acetate
(PMA), Ionomycin (Calbiochem), and Brefeldin A (BioLegend). Cells were
collected and stained for surface markers and intracellular cytokines
(BioLegend) according to Foxp3/Transcription Factor Staining buffer set
(eBioscience). Flow cytometry was performed on a LSRII instrument (BD
Biosciences). Cell populations were sorted from peritoneal washes of OvCa-
bearing mice or human ascites or tumor single-cell suspensions with a
FACSAria sorter (BD Biosciences), and flow cytometry data were analyzed
using FlowJo v.9 or v.10.
Statistical Analysis
Unless noted otherwise, all experiments were repeated at least two times and
results were similar between repeats. Animal experiments used between three
and six mice per group; p < 0.05 was considered to be statistically significant.
All statistical analyses were done using Graph Pad Prism 5.0. Differences be-
tween the means of experimental groups were calculated using a two-tailed
unpaired Student’s t test. Error bars represent SEM from independent samples
assayed within the represented experiments. Survival rates were compared
using the log-rank test. All survival experiments used at least six mice per
group. This number provides a 5% significance level and 95% power to detect
differences in survival of 20% or greater.ACCESSION NUMBERS
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